Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Frandsen

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Diabetes, Obesity & Metabolism|March 30, 2007
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trialS S Lund, L Tarnow, C D A Stehouwer, et al.
Molecular Therapy. Nucleic Acids|June 22, 2016
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human PrimatesMaria Eugenia Gallo Cantafio, Boye Schnack Nielsen, Chiara Mignogna, et al.
Lancet (London, England)|November 14, 2001
Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective studyC Ellervik, T Mandrup-Poulsen, B G Nordestgaard, et al.
Chemical Science|December 22, 2022
Synergistic effect of p-type and n-type dopants in semiconductors for efficient electrocatalytic water splittingTugce Kutlusoy, Spyridon Divanis, Rebecca Pittkowski, et al.
Diabetes, Obesity & Metabolism|June 30, 2009
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetesS S Lund, L Tarnow, A S Astrup, et al.
Plos One|March 4, 2014
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cellsMaria Teresa Di Martino, Annamaria Gullà, Maria Eugenia Gallo Cantafio, et al.
Blood|July 13, 2018
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92Eugenio Morelli, Lavinia Biamonte, Cinzia Federico, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Diabetes, Obesity & Metabolism|March 30, 2007
Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trialS S Lund, L Tarnow, C D A Stehouwer, et al.
Molecular Therapy. Nucleic Acids|June 22, 2016
Pharmacokinetics and Pharmacodynamics of a 13-mer LNA-inhibitor-miR-221 in Mice and Non-human PrimatesMaria Eugenia Gallo Cantafio, Boye Schnack Nielsen, Chiara Mignogna, et al.
Lancet (London, England)|November 14, 2001
Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective studyC Ellervik, T Mandrup-Poulsen, B G Nordestgaard, et al.
Chemical Science|December 22, 2022
Synergistic effect of p-type and n-type dopants in semiconductors for efficient electrocatalytic water splittingTugce Kutlusoy, Spyridon Divanis, Rebecca Pittkowski, et al.
Diabetes, Obesity & Metabolism|June 30, 2009
Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetesS S Lund, L Tarnow, A S Astrup, et al.
Plos One|March 4, 2014
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cellsMaria Teresa Di Martino, Annamaria Gullà, Maria Eugenia Gallo Cantafio, et al.
Blood|July 13, 2018
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92Eugenio Morelli, Lavinia Biamonte, Cinzia Federico, et al.
Pageof 3